Biological disease‐modifying drugs for rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1836
Abstract: There are now nine biological disease‐modifying antirheumatic drugs (bDMARDs) available for the treatment of rheumatoid arthritis – seven monoclonal antibodies and two fusion proteins. This article summarises their indications, efficacy, place in therapy and adverse… read more here.
Keywords: drugs rheumatoid; disease modifying; biological disease; rheumatoid arthritis ... See more keywords
Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011
Sign Up to like & getrecommendations! Published in 2018 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-018-1321-4
Abstract: SummaryBackgroundRheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed… read more here.
Keywords: modifying antirheumatic; drug survival; disease modifying; biological disease ... See more keywords
Real-life data of survival and reasons for discontinuation of biological disease-modifying drugs ‘in’ rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-020-01171-5
Abstract: Background Rheumatoid arthritis is a chronic, autoimmune disease in which treatment has evolved with a variety of therapeutic classes. Biological disease-modifying antirheumatic drugs have improved therapy; however, the continued long-term use of these drugs with… read more here.
Keywords: disease modifying; disease; biological disease; rheumatoid arthritis ... See more keywords
The association between the biological disease-modifying anti-rheumatic drugs and the incidence of diabetes: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "Pharmacological research"
DOI: 10.1016/j.phrs.2020.105216
Abstract: Whether the use of biological disease-modifying anti-rheumatic drugs (bDMARDs) would influence the risk of new-onset diabetes remains uncertain. Therefore, we performed a systematic review and meta-analysis to evaluate the association between the use of bDMARDs… read more here.
Keywords: incidence; modifying anti; anti rheumatic; incidence diabetes ... See more keywords
Effectiveness of Tacrolimus Concomitant with Biological Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac025
Abstract: OBJECTIVES The study aimed to investigate the effectiveness and tolerance of biological disease-modifying antirheumatic drugs (bDMARDs) therapy administered concomitantly with tacrolimus (TAC) treatment in patients with rheumatoid arthritis. METHODS 2792 patients who underwent therapy with… read more here.
Keywords: tac group; group; tac; patients rheumatoid ... See more keywords
Reasons and Risk Factors For Discontinuation of Treatment with Any Biological Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis: A Long-term Observational Study.
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac090
Abstract: OBJECTIVES Patients with rheumatoid arthritis (RA) usually switch to a second biological disease-modifying antirheumatic drugs (bDMARDs) when the first has proven ineffective, although some may discontinue bDMARDs treatment altogether. We investigated the total rate of… read more here.
Keywords: patients rheumatoid; rheumatoid arthritis; biological disease; risk ... See more keywords
Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study
Sign Up to like & getrecommendations! Published in 2023 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-223636
Abstract: Objective Assess cancer risks with Janus kinase inhibitors (JAKi) versus biological disease-modifying antirheumatic drugs (bDMARDs) in clinical practice. Methods Cohort study of patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) initiating treatment with JAKi,… read more here.
Keywords: antirheumatic drugs; biological disease; disease modifying; modifying antirheumatic ... See more keywords
The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2023 at "Internal Medicine"
DOI: 10.2169/internalmedicine.9600-22
Abstract: Objective Sarcopenia is characterized by a loss of muscle mass and strength, which leads to frailty and mortality. Rheumatoid arthritis (RA) is considered to be a cause of sarcopenia. The present study assessed the effectiveness… read more here.
Keywords: disease; rheumatoid arthritis; status; biological disease ... See more keywords
Healthcare Professionals’ Compliance with the Standard Management Guidelines towards the Use of Biological Disease-Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Environmental Research and Public Health"
DOI: 10.3390/ijerph19084699
Abstract: Treatment of rheumatoid arthritis (RA) is complicated, with numerous aspects influencing decision-making, including disease severity, comorbidities, and patient preferences. The present study aimed to evaluate healthcare professionals’ (HCPs) knowledge of biological disease-modifying anti-rheumatic drugs (bDMARDs)… read more here.
Keywords: management guidelines; rheumatoid arthritis; standard management; management ... See more keywords